5Karavitaki N, Cudlip S, Adams CB, et al . Craniopharyngiomas [J]. Endocr Rev, 2006, 27(4): 371-397.
6Ullrich N J, Scott RM, Pomeroy SL. Craniopharyngioma therapy: long-term effects on hypothalamic function [J]. Neurologist, 2005, 11(1): 55-60.
7Samii M, Tatagiba M. Surgical management of craniopharyngiomas: a review [J]. Neurol Med Chir (Tokyo), 1997, 37 (2): 141-149.
8Kiran NA, Suri A, Kasliwal MK, et al . Gross total excision of pediatric giant cystic craniopharyngioma with huge retroclival extension to the level of foramen magnum by anterior transpetrous approach: report of two cases and review of literature [J]. Childs Nerv Syst, 2008, 24(3): 385-391.
9Smith ER, Manfredi M, Scott RM, et al . A recurrent craniopharyngioma illustrates the potential usefulness of urinary matrix metalloproteinases as noninvasive biomarkers: case report [J]. Neurosurgery, 2007, 60(6): 1148-1149.
10Xu J, You C, Zhang S, et al . Angiogenesis and cell proliferation in human craniopharyngioma xenografts in nude mice [J]. J Neurosurg, 2006, 105(4 Suppl): 306-310.
7Salmaggi A, Maderna E, Calatozzolo C, et al. CXCL12, CXCR4 and CXCR7 expression in brain metastases [ J ]. Cancer Biol Ther, 2009,8 ( 17 ) : 1608 - 1614.
8Iwasa S, Yanagawa T, Fan J, et al. Expression of CXCR4 and its ligand SDF - 1 in intestinal - type gastric cancer is associated with lymph node and liver metastasis[ J]. Anticancer Res ,2009,29( 11 ) :4751 -4758.
9Zeng Z, Shi YX, Samudio IJ, et al. Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML [ J ]. Blood,2009,113 ( 24 ) : 6045 - 6046.
10Kalinkovich A, Tavor S, Avigdor A, et al. Functional CXCR4 -expressing rnicroparticles and SDF -1 correlate with circulating acute rnyelogenous leukemia cells [ J ]. Cancer Res,2006,66 ( 22 ) : 11013 - 11020.
